Impatto economico dell’utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane

Carla Rognoni; Rosanna Tarricone; Michela Meregaglia

doi:10.3280/MESA2015-023006

Impatto economico dell’utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane

Journal title MECOSAN
Author/s Carla Rognoni, Rosanna Tarricone, Michela Meregaglia
Publishing Year 2015 Issue 2015/93
Language Italian Pages 16 P. 99-114 File size 1113 KB
DOI 10.3280/MESA2015-023006
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Iron deficiency anemia is the most common form of anemia observed in clinical practice. The infusion of intravenous iron quanhas proved to be safe and effective and to quickly lead patients to normal hemoglobin levels. Starting from the collection of healthcare resources consumption in five Italian hospitals, the economic impact of the management of patients with iron deficiency anemia in Italy on hospitals and regional health systems has been estimated considering different scenarios of utilization of ferric carboximaltose (FCM) and ferric gluconate (FG). Regional reimbursement tariffs have been used to estimate the economic burden from the perspective of the regional systems, while the cost function related to different inputs was used for the hospital perspective. Assuming a full replacement of FG by FCM, the maximum savings achievable by the Italian health system would be approximately 34 million euro. From the hospital perspective, with a single infusion of 1000 mg of FCM, at the current cost of 131,24 €, it is possible to get savings of 75% compared to 16 infusions of FG 62.5 mg each and 50% compared to 8 infusions of two vials of FG each (125 mg). In conclusion, FCM can be considered a cost-saving option, from both regional health systems and hospital point of views, as compared to the currently and widely adopted iron formulation for the treatment of patients with iron deficiency anemia in Italy.

Keywords: Iron deficiency anemia, ferric carboxymaltose, ferric gluconate, cost, budget impact.

Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion Joana Marinho, Inês Leão, Sandra Custódio, Enrique Dias, António Moreira Pinto, Telma Costa, Andreia Capela, Margarida Dias, Henrique Coelho, Ângela Cunha, Ana Macedo, Anabela Amarelo, Ana Joaquim, in Scientific Reports 20410/2019
DOI: 10.1038/s41598-019-56999-3

Carla Rognoni, Rosanna Tarricone, Michela Meregaglia, Impatto economico dell’utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane in "MECOSAN" 93/2015, pp 99-114, DOI: 10.3280/MESA2015-023006